Compare JMIA & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | AZTA |
|---|---|---|
| Founded | 2012 | 1978 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2019 | 1995 |
| Metric | JMIA | AZTA |
|---|---|---|
| Price | $12.19 | $35.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $16.50 | ★ $43.60 |
| AVG Volume (30 Days) | ★ 3.0M | 809.0K |
| Earning Date | 11-12-2025 | 11-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $173,224,000.00 | ★ $593,821,000.00 |
| Revenue This Year | $18.22 | $6.13 |
| Revenue Next Year | $16.76 | $5.02 |
| P/E Ratio | ★ N/A | $66.60 |
| Revenue Growth | N/A | ★ 3.55 |
| 52 Week Low | $1.60 | $23.91 |
| 52 Week High | $13.44 | $55.64 |
| Indicator | JMIA | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 56.05 |
| Support Level | $11.30 | $34.41 |
| Resistance Level | $13.44 | $38.22 |
| Average True Range (ATR) | 0.78 | 1.68 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 67.62 | 25.52 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.